XML 45 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Operating Segments (Tables)
6 Months Ended
Jun. 30, 2021
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information

The table below presents certain financial information of our operating segments for the three and six months ended June 30, 2021 and 2020 (in thousands):

 

Segment Reporting for the Quarter Ended June 30, 2021

 

     Treatment     Services   Medical   Segments Total   Corporate (1)   Consolidated Total 
Revenue from external customers  $7,706   $8,439       $16,145   $   $16,145 
Intercompany revenues   319    32        351         
Gross profit (negative gross profit)   1,433    (467)       966        966 
Research and development   43    19    72    134    10    144 
Interest income                   2    2 
Interest expense   (18)           (18)   (47)   (65)
Interest expense-financing fees                   (9)   (9)
Depreciation and amortization   310    85        395    5    400 
Segment income (loss) before income taxes   471    (1,292)   (72)   (893)   4,027(2)   3,134 
Income tax expense   3    10        13        13 
Segment income (loss)   468    (1,302)   (72)   (906)   4,027    3,121 
Expenditures for segment assets   270    10        280    9    289(3)

 

Segment Reporting for the Quarter Ended June 30, 2020

 

     Treatment     Services   Medical   Segments Total   Corporate (1)   Consolidated Total 
Revenue from external customers  $7,840   $14,207       $22,047   $   $22,047 
Intercompany revenues   446    5        451         
Gross profit   1,695    1,615        3,310        3,310 
Research and development   52    46    74    172    37    209 
Interest income   1            1    27    28 
Interest expense   (28)   (4)       (32)   (67)   (99)
Interest expense-financing fees                   (60)   (60)
Depreciation and amortization   275    84        359    5    364 
Segment income (loss) before income taxes   750    1,031    (74)   1,707    (1,456)   251 
Income tax benefit   (9)           (9)       (9)
Segment income (loss)   759    1,031    (74)   1,716    (1,456)   260 
Expenditures for segment assets   320    146        466    2    468(4)

 

Segment Reporting for the Six Months Ended June 30, 2021

 

     Treatment     Services   Medical   Segments Total   Corporate (1)   Consolidated Total 
Revenue from external customers  $15,201   $24,077       $39,278   $   $39,278 
Intercompany revenues   979    39        1,018         
Gross profit   2,358    964        3,322        3,322 
Research and development   90    32    149    271    24    295 
Interest income                  21    21 
Interest expense   (37)   (8)       (45)   (87)   (132)
Interest expense-financing fees                   (17)   (17)
Depreciation and amortization   620    170        790    9    799 
Segment income (loss) before income taxes   352    (737)   (149)   (534)   2,613(2)   2,079 
Income tax (benefit) expense   (14)   10        (4)       (4)
Segment income (loss)   366    (747)   (149)   (530)   2,613    2,083 
Expenditures for segment assets   627    14        641    9    650(3)

 

Segment Reporting for the Six Months Ended June 30, 2020

 

     Treatment     Services   Medical   Segments Total   Corporate (1)   Consolidated Total 
Revenue from external customers  $17,403   $29,504       $46,907   $   $46,907 
Intercompany revenues   653    13        666         
Gross profit   4,440    3,510        7,950        7,950 
Research and development   145    112    140    397    44    441 
Interest income   1            1    83    84 
Interest expense   (46)   (10)       (56)   (163)   (219)
Interest expense-financing fees                   (129)   (129)
Depreciation and amortization   539    162        701    10    711 
Segment income (loss) before income taxes   2,297    2,349    (140)   4,506    (2,933)   1,573 
Income tax expense   5            5        5 
Segment income (loss)   2,292    2,349    (140)   4,501    (2,933)   1,568 
Expenditures for segment assets   1,000    361        1,361    5    1,366(4)

 

(1) Amounts reflect the activity for corporate headquarters not included in the segment information.

 

(2) Amounts includes approximately $5,381,000 of “Gain on extinguishment of debt” recorded in connection with the Company’s PPP Loan which was forgiven by the SBA effective June 15, 2021 (see “Note 8 – Long Term Debt – PPP Loan” for information of this loan forgiveness).

 

(3) Net of financed amount of $0 and $29,000 for the three and six months ended June 30, 2021, respectively.

 

(4) Net of financed amount of $51,000 and $132,000 for the three and six months ended June 30, 2020, respectively.